Silo Pharma Finalizes Warrants Offering to Raise Up to $3.0M, Potential 30% Dilution

summarizeSummary

Silo Pharma finalized a warrants offering priced at a premium to its current stock, potentially raising up to $3.0 million for working capital, but introducing significant dilution of over 30%.

check_boxKey Events

• Warrants Offering Finalized

  The company finalized a public offering of 2,416,670 Series A-1 Warrants, 2,356,670 Series A-2 Warrants, and up to 250,000 Placement Agent Warrants, along with the underlying common stock.

• Potential Capital Raise

  Silo Pharma may receive up to approximately $3.0 million in aggregate gross proceeds from the cash exercise of these warrants, which will be used for general working capital and corporate purposes.

• Significant Potential Dilution

  The offering could result in a potential dilution of approximately 30.88% if all 5,023,340 warrants are fully exercised into common stock.

• Premium Pricing

  The public offering price for the common stock purchase warrants and their exercise price of $0.60 (or $0.75 for placement agent warrants) is at a premium to the current market price of $0.498699 per share.

auto_awesomeAnalysis

Silo Pharma, a developmental-stage biopharmaceutical and cryptocurrency company, has finalized the terms for a public offering of Series A-1 and A-2 common stock purchase warrants, along with placement agent warrants. This offering, which follows a previous 424B3 filing on April 14, 2026, sets the public offering price for each common stock purchase warrant at $0.60, with an exercise price of $0.60 for the A-1 and A-2 warrants, and $0.75 for the placement agent warrants. Notably, these prices are at a premium to the current stock price of $0.498699. The company may receive up to approximately $3.0 million in gross proceeds from the cash exercise of these warrants, which is a substantial amount relative to its current market capitalization. These proceeds are intended for general working capital, capital expenditures, and product development. The offering introduces significant potential dilution of approximately 30.88% if all warrants are exercised. This capital raise is critical for the company, especially given its ongoing net losses, increased cash burn, and a Nasdaq delisting threat due to its minimum bid price requirement.